← Back to All Stocks

NRx Pharmaceuticals, Inc. (NRXP) Analysis

Generated on: 2025-07-31 13:26:40 UTC
All stock prices are delayed.
Use of this site does not constitute financial advice.
⚠️ VERY LOW FLOAT STOCK - 13,364,027 shares

Analysis Values

Current Price
$2.97
Predicted Price
$2.11
Expected Return
-20.77%
Confidence Score
0.83
RSI (14)
17.14 (buy)
MACD
-0.07
Volume
155,900
Float Shares
13,364,027
Reddit Posts
0
News Items
1
SEC Filings
0
Data Points
250

NRXP

NRx Pharmaceuticals, Inc.
-20.77%
Price: $2.97
Confidence: 0.83
News
Low Float
RSI Buy
Last updated: 2025-07-31 13:26:39

Technical Analysis

RSI: 17.14 (buy)
MACD: -0.07
Technical Analysis Graph

Risk Analysis

Volatility
118.69%
Max Drawdown
-66.47%
Beta
1.0
Risk Score
94.1

Social Sentiment

0
Social Sentiment Score (0-100)

Recent News

News thumbnail
Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
TipRanks - 2025-06-27 15:50
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a primary endpoint achievement, a clinical site addition and additional development candidate data. COMPASS PATHWAYS ACHIEVES PRIMARY ENDPOINT IN COMP360 TRIAL: Compass Pathways (CMPS) announced Monday the achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, fo

Reddit Discussions

No recent Reddit discussions found.

Recent SEC Filings

No recent SEC filings found.